Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cachexia: lessons from melanocortin antagonism.

Mark D Deboer1, Daniel L Marks

  • 1Department of Pediatrics, Oregon Health and Science University, 707 SW Gaines Rd., Portland, Oregon 97239, USA. marksd@ohsu.edu

Trends in Endocrinology and Metabolism: TEM
|June 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human-milk vitamin B-3 (niacin and vitamer) concentrations: secondary analysis of a randomized, placebo-controlled trial of maternal nicotinamide supplementation in rural Tanzania.

The American journal of clinical nutrition·2026
Same author

Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity.

Nature communications·2026
Same author

Metabolic syndrome severity is related to perceived discrimination and stress in the all of us cohort.

Comprehensive psychoneuroendocrinology·2026
Same author

Free testosterone independently predicts metabolic syndrome severity in U.S. adolescent girls aged 12-19 years.

Journal of the Endocrine Society·2026
Same author

The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives.

Frontiers in endocrinology·2026
Same author

Endogenous targeting lipid nanoparticles for systemic mRNA delivery to lung cancer tumors.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Mitochondria setting the stage for ferroptosis.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Mitochondria produce lactate to vent redox pressure.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Beyond fat storage: neuronal lipid droplets regulate whole-body metabolism.

Trends in endocrinology and metabolism: TEM·2026
Same journal

HDL resuscitates cells from ferroptosis.

Trends in endocrinology and metabolism: TEM·2026
Same journal

2-Methylbutyrylcarnitine (2MBC).

Trends in endocrinology and metabolism: TEM·2026
Same journal

Decoding growth hormone actions on human growth plate stem cells.

Trends in endocrinology and metabolism: TEM·2026
See all related articles

Melanocortin signaling blockade, specifically targeting the MC4 receptor, effectively reduces disease-associated wasting and anorexia in rodent models. This finding offers a potential therapeutic strategy for cachexia, a condition worsening disease prognosis.

Area of Science:

  • Neuroendocrinology
  • Metabolic Disorders
  • Oncology

Background:

  • Melanocortin system disruptions in the central nervous system (CNS) are linked to morbid obesity.
  • Emerging evidence implicates melanocortin system activation in the development of cachexia (disease-associated wasting).
  • Pro-opiomelanocortin (POMP) neurons, expressing cytokine receptors, are activated by cytokines elevated in cachexia-associated diseases.

Purpose of the Study:

  • To investigate the role of melanocortin signaling in disease-associated cachexia.
  • To evaluate the efficacy of melanocortin MC4 receptor antagonists in mitigating cachexia in preclinical models.

Main Methods:

  • Utilized rodent models of cancer and renal failure, which are associated with cachexia.
  • Administered antagonists to the melanocortin MC4 receptor to block melanocortin signaling.

Related Experiment Videos

  • Assessed the impact of the blockade on anorexia and wasting.

    • Main Results:

    • Blockade of melanocortin signaling via MC4 receptor antagonists significantly attenuated anorexia.
    • Disease-associated wasting was effectively reduced in the treated rodent models.
    • Inhibition of cachexia improved outcomes in models of cancer and renal failure.

    Conclusions:

    • Activation of the melanocortin system contributes to the pathogenesis of cachexia.
    • Targeting the melanocortin MC4 receptor represents a promising therapeutic approach for managing cachexia.
    • Reducing cachexia through melanocortin signaling inhibition can improve disease prognosis.